Navigation Links
Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
Date:10/26/2008

IV genome (from their blood sample) and then uses it to make HIV particles containing the patient's virus envelope protein. The resultant HIV particles are then used to infect cells that contain the CCR5 co-receptor or the CXCR4 co-receptor on the cell surface. Once the virus infects the cell, it undergoes a single round of replication. Virus replication results in the production of luciferase from a luciferase gene that is carried into the cell by the virus. The production of luciferase in either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor tropism of the patient virus. Trofile is the only clinically validated tropism assay and has been used to select patients in all phase II and phase III studies of CCR5 antagonists to date.

In June 2008, optimization of Trofile made it substantially more sensitive at identifying very low levels of CXCR4 using virus (X4 or dual/mixed tropic) in HIV-1 patient samples while maintaining a high degree of accuracy. The assay can now detect X4 virus present at levels less than 0.3% of the total virus population, and at that level of X4 virus, the assay is 100% sensitive.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking, including stateme
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
4. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
5. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
8. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
(Date:8/21/2014)... 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), ... regenerative medicine, announced today the appointments of Andrew ("Andy") ... expanded Board of Directors. With these additions, the Asterias ... whom are independent. Andy Arno , ... growth companies. He is currently Managing Director of Emerging ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 9, 2011 UCL Business (UCLB), a wholly owned ... Dickinson and Company), a leading global medical technology company, ... detection of ovarian and breast cancers to ultimately enable ... demonstrates how UCL and the Institute for Women,s Health ...
... Feb. 9, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... an investor briefing on Sunday, February 13 from 9 ... briefing, principal investigators from the VEGF Trap-Eye clinical studies ... Angiogenesis, Exudation and Degeneration 2011 meeting being held in ...
Cached Medicine Technology:BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 2BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 3BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 2Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 3Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 5
(Date:8/21/2014)... 21, 2014 According to a new ... Device System Market- Global Industry Analysis, Size, Share, Growth, ... device market was valued at USD 1,531.2 million in ... of 22.8% from 2013 to 2019, to reach an ... Globally, the microfluidic device market is witnessing significant growth ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... the Medical Cannabis Network that a company located in ... to be the only marijuana patient verification ... like to welcome this new entity to our growing ... due to our belief that these claims are inaccurate. ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Researchers report that ... cellular connections -- in their brains compared with typical ... possible to reduce the number of extra synapses through ... brain where brain cells (neurons) connect and communicate with ... impact on how the brain functions, theorized neuroscientists at ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the nation’s ... to announce Trinity Benefit Advisors as its newest ... Benefit Advisors is a full service firm that ... Their consultative approach is comprised of four components: ... monitoring. Their dedication to effective results and absolute ...
(Date:8/21/2014)... 2014 The report "Indoor ... Hybrid), Maps and Navigation, Location based analytics, ... - Worldwide Market Forecasts and Analysis (2014 ... location market into various sub-segments with an ... report also identifies the factors driving this ...
Breaking Medicine News(10 mins):Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 4
... Do adolescents get enough exercise and eat the right ... Researchers analyzed the behavior of almost 900 11-to-15 year-olds ... and dietary risk behaviors, almost half had at least ... of the health guidelines in the study. ...
... the protein EGFR are important for the development of lung ... However, not all individuals// express the same mutant EGFR, for ... of EGFR and some have a mutation that affects the ... ,The potential of therapeutics to benefit individuals with ...
... The most recent Cochrane Review concluded antidepressants bupropion (Zyban) ... smoking and have few side-effects, but selective Serotonin reuptake ... ,Although nicotine medications are known to ... them or wants to use them. One possible alternative ...
... new report finds that less number of women aged 40 ... declining mammography rate could mean more breast cancer deaths down ... rates kept increasing during the 1990s, and scientists are disturbed ... reminded that, despite mammography being a test that's been around ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...
Cached Medicine News:Health News:Assessing Diet and Exercise Behaviors in Adolescents 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... an Entire Column of a 384 Well Plate ... with 384 well plates, you need a pipettor ... Thats exactly what you get with our 16-channel ... (see Impact/Impact2), this innovation was specifically designed to ...
... a 384 Well Plate at Once , To ... you need a pipettor that can adapt to ... get with our 16-channel Impact pipettor., Available with ... was specifically designed to allow you to transfer ...
Medicine Products: